OpGen’s Subsidiary Ares Genetics Commercially Launches New Sequencing and Analysis Services Globally
April 20 2022 - 6:30AM
OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine
company harnessing the power of molecular diagnostics and
informatics to help combat infectious disease, announced today that
its subsidiary, Ares Genetics (“Ares”), which strives to become a
leader in bacterial genomics and AI-powered prediction of
antimicrobial resistance (AMR), is commercially launching a series
of new genome sequencing and analysis services globally.
In March 2022, the WHO emphasized the critical importance of
microbial genome sequencing for pandemic preparedness in its new
10-year strategy1 for the global genomic surveillance of pathogens
with pandemic and epidemic potential. To help curb the global
spread of antimicrobial resistance (AMR) pathogens, Ares Genetics
is expanding its commercial offering of sequencing and analysis
services aimed at clinical microbiologists and specialists in
public health and infection prevention and control. The new
services include ARESid and ARESiss Express.
ARESid enables accurate and comprehensive detection and
surveillance of bacterial and fungal microbes in a culture-free
fashion directly from native patient specimen or environmental
samples. Due to the semi-quantitative nature of ARESid, the
sequencing and analysis service is equally suitable for pathogen
detection and for microbiome profiling applications.
ARESiss Express accelerates the company’s well-established
platform for whole genome sequencing of clinical isolates. “We are
delighted to respond to customer demand by introducing ARESiss
Express,” said Dr. Arne Materna, CEO of Ares Genetics. “ARESiss
Express builds on our clinically validated platform for whole
genome sequencing of bacterial isolates but reduces turnaround
times from ARESiss by more than 80% to five business days in order
to enable microbiologists and epidemiologists to analyze and
respond to local outbreaks in a timely manner.”
ARESiss Express reports include outbreak relevant information -
for instance on pathogen identity and type - as well as actionable
information on AMR, thanks to the company’s proprietary technology
enabling the AI-powered prediction of antibiotic susceptibility and
resistance directly from genomic data for a wide range of pathogen
drug combinations.
ARESid and ARESiss Express sequencing results are accessible to
customers via AREScloud, a web application for which the company
plans to release a number of new features over the coming
months.
Customers can submit orders for both sequencing services, to be
performed at Ares Genetics’ service laboratory in Vienna, Austria.
U.S.-based sequencing services will be launched later this year
Customers looking to enhance their data interpretation pipelines
can access the AREScloud platform immediately by subscription to
the service.
All Ares Genetics products and services are for research use
only.
About OpGen, Inc. OpGen,
Inc. (Rockville, MD, USA) is a precision medicine company
harnessing the power of molecular diagnostics and bioinformatics to
help combat infectious disease. Along with our
subsidiaries, Curetis GmbH and Ares Genetics GmbH,
we are developing and commercializing molecular microbiology
solutions helping to guide clinicians with more rapid and
actionable information about life threatening infections to improve
patient outcomes and decrease the spread of infections caused by
multidrug-resistant microorganisms, or MDROs. OpGen’s product
portfolio includes Unyvero, Acuitas AMR Gene Panel, and the
ARES Technology Platform including ARESdb, using NGS technology and
AI-powered bioinformatics solutions for antibiotic response
prediction.
For more information, please visit www.opgen.com.
Forward-Looking Statements
This press release includes statements regarding the launch of
new services by Ares Genetics. These statements and other
statements regarding OpGen’s future plans and goals constitute
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934 and are intended to qualify for the safe
harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Such statements are subject to risks
and uncertainties that are often difficult to predict, are beyond
our control, and which may cause results to differ materially from
expectations. Factors that could cause our results to differ
materially from those described include, but are not limited to,
the success of our commercialization efforts, our ability to
successfully, timely and cost-effectively develop, seek and obtain
regulatory clearance for and commercialize our product and services
offerings, the rate of adoption of our products and services by
hospitals and other healthcare providers, the fact that we may not
effectively use proceeds from recent financings, the continued
realization of expected benefits of our business combination
transaction with Curetis GmbH, the continued impact of
COVID-19 on the Company’s operations, financial results, and
commercialization efforts as well as on capital markets and general
economic conditions, the effect of the military action
in Russia and Ukraine on our distributors,
collaborators, and service providers, our liquidity and working
capital requirements, the effect on our business of existing and
new regulatory requirements, and other economic and competitive
factors. For a discussion of the most significant risks and
uncertainties associated with OpGen's business, please
review our filings with the Securities and Exchange
Commission. You are cautioned not to place undue reliance on these
forward-looking statements, which are based on our expectations as
of the date of this press release and speak only as of the date of
this press release. We undertake no obligation to publicly update
or revise any forward-looking statement, whether as a result of new
information, future events or otherwise.
1: World Health Organization, Global genomic surveillance
strategy for pathogens with pandemic and epidemic potential,
2022–2032. 32 (2022). ISBN: 9789240046979
OpGen:Oliver SchachtPresident and
CEOInvestorRelations@opgen.com
OpGen Press Contact:Matthew
Bretzius FischTank Marketing and
PRmatt@fischtankpr.com
OpGen Investor Contact:Alyssa
FactorEdison Groupafactor@edisongroup.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Sep 2024 to Oct 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Oct 2023 to Oct 2024